We have further shown the specificity and versatilityof LTzC by click-to-release activation of prodrugs andselective killing of PD-L1-expressing breast cancer cells, offeringa new multimodal approach to “track-&-treat” malignantcells that are capable of evading the immune system. The gene discussed is CD274; the disease is breast carcinoma.